57 related articles for article (PubMed ID: 11782376)
1. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
[TBL] [Abstract][Full Text] [Related]
3. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
Araki E; Ishikawa M; Iigo M; Koide T; Itabashi M; Hoshi A
Jpn J Cancer Res; 1993 Jun; 84(6):697-702. PubMed ID: 8340259
[TBL] [Abstract][Full Text] [Related]
4. Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo.
Zhu H; Lu C; Gao F; Qian Z; Yin Y; Kan S; Chen D
Biomed Pharmacother; 2021 Nov; 143():112192. PubMed ID: 34649340
[TBL] [Abstract][Full Text] [Related]
5. Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.
Meng J; Abu YF; Zhang Y; Zhou Y; Xie Y; Yan Y; Tao J; Ramakrishnan S; Chen C; Roy S
Br J Pharmacol; 2023 May; 180(10):1362-1378. PubMed ID: 36562107
[TBL] [Abstract][Full Text] [Related]
6. Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition.
Yu Y; Kong R; Cao H; Yin Z; Liu J; Nan X; Phan AT; Ding T; Zhao H; Wong STC
Oncotarget; 2018 Jun; 9(46):27958-27973. PubMed ID: 29963254
[TBL] [Abstract][Full Text] [Related]
7. Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.
Eades W; Liu W; Shen Y; Shi Z; Yan B
Curr Drug Metab; 2022 Dec; ():. PubMed ID: 36515038
[TBL] [Abstract][Full Text] [Related]
8. Intestinal Flora in Chemotherapy Resistance of Biliary Pancreatic Cancer.
Bai L; Yan X; Lv J; Qi P; Song X; Zhang L
Biology (Basel); 2023 Aug; 12(8):. PubMed ID: 37627035
[TBL] [Abstract][Full Text] [Related]
9. Clinical review of alkalization therapy in cancer treatment.
Hamaguchi R; Isowa M; Narui R; Morikawa H; Wada H
Front Oncol; 2022; 12():1003588. PubMed ID: 36185175
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Swami U; Goel S; Mani S
Curr Drug Targets; 2013 Jun; 14(7):777-97. PubMed ID: 23597015
[TBL] [Abstract][Full Text] [Related]
11. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
Weiss GJ; Chao J; Neidhart JD; Ramanathan RK; Bassett D; Neidhart JA; Choi CHJ; Chow W; Chung V; Forman SJ; Garmey E; Hwang J; Kalinoski DL; Koczywas M; Longmate J; Melton RJ; Morgan R; Oliver J; Peterkin JJ; Ryan JL; Schluep T; Synold TW; Twardowski P; Davis ME; Yen Y
Invest New Drugs; 2013 Aug; 31(4):986-1000. PubMed ID: 23397498
[TBL] [Abstract][Full Text] [Related]
12. Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.
Takakura A; Kurita A; Asahara T; Yokoba M; Yamamoto M; Ryuge S; Igawa S; Yasuzawa Y; Sasaki J; Kobayashi H; Masuda N
Oncol Lett; 2012 Mar; 3(3):520-524. PubMed ID: 22740943
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer.
Yoshioka T; Kato S; Gamoh M; Chiba N; Suzuki T; Sakayori N; Kato S; Shibata H; Shimodaira H; Otsuka K; Kakudo Y; Takahashi S; Ishioka C
Br J Cancer; 2009 Dec; 101(12):1972-7. PubMed ID: 19920821
[TBL] [Abstract][Full Text] [Related]
14. Modifications of human carboxylesterase for improved prodrug activation.
Hatfield JM; Wierdl M; Wadkins RM; Potter PM
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1153-65. PubMed ID: 18721110
[TBL] [Abstract][Full Text] [Related]
15. Small cell carcinoma of the prostate treated with amrubicin.
Katou M; Soga N; Onishi T; Arima K; Sugimura Y
Int J Clin Oncol; 2008 Apr; 13(2):169-72. PubMed ID: 18463964
[TBL] [Abstract][Full Text] [Related]
16. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
Valentí Moreno V; Brunet Vidal J; Manzano Alemany H; Salud Salvia A; Llobera Serentill M; Cabezas Montero I; Servitja Tormo S; Sopena Bert E; Gumà Padró J
Clin Transl Oncol; 2006 Mar; 8(3):208-12. PubMed ID: 16648121
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Takeda Y; Tsuduki E; Izumi S; Hojo M; Kamimura M; Naka G; Kobayashi K; Kudo K
Br J Cancer; 2005 Dec; 93(12):1341-9. PubMed ID: 16288302
[TBL] [Abstract][Full Text] [Related]
19. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Hu Z; Yang X; Ho PC; Chan E; Chan SY; Xu C; Li X; Zhu YZ; Duan W; Chen X; Huang M; Yang H; Zhou S
Pharm Res; 2005 Jun; 22(6):902-14. PubMed ID: 15948034
[TBL] [Abstract][Full Text] [Related]
20. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
Fittkau M; Voigt W; Holzhausen HJ; Schmoll HJ
J Cancer Res Clin Oncol; 2004 Jul; 130(7):388-94. PubMed ID: 15160289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
